The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

WithdrawnOBSERVATIONAL

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions

Metabolic Health

Interventions

DRUG

Tirzepatide

Once-weekly subcutaneous injectable

DRUG

Semaglutide

Once-weekly subcutaneous injectable